Search PubMed⌕ Search

Biomedical subjects

N Ragni

Publications and source records attributed to N Ragni.

112 records · Page 7Linked to original sources
PubMedDate not supplied

[Primary dysmenorrhea treated with sublingual piroxicam].

Open non comparative study for the evaluation of the efficacy and tolerability of the new piroxicam formulation, the Fast Dissolving Dosage Form tablets for sublingual administration in the treatment of primary dysmenorrhea. The 54 patients enrolled in the study have been treated with piroxicam sublingual tablets: 40 mg single daily dose for the first two days and 20 mg for the following three days for a total of 5 days of therapy to be repeated for two consecutive menstrual cycles. The drug efficacy was evaluated on the basis of variation of intensity in pain and associated symptoms, as cephalgia, nausea, vomiting, etc. The ability to perform normal daily activity has also been evaluated. The intensity of spontaneous pain in the first and second cycles showed a statistically significant improvement (p = 0.0001) only 15 minutes after drug administration. This improvement increased in the first and in the following days. The relief from pain was stronger in the second cycle, in fact none of the patients had to assume a further analgesic drug, as happened during the first cycle of therapy. As regards the symptoms associated to pain, as cephalgia and low back pain, they significatively decreased starting from the first cycle of treatment. The improvement became more marked during the second cycle of therapy. Local and systemic tolerability was good. Only 5 patients experienced systemic side effects in the first cycle, and 12 in the second cycle. Three patients experienced local side effects in the first cycle, and 1 in the second cycle. These effects were well tolerated and did not cause the treatment discontinuation. Moreover, most of the side effects occurred, as nausea and diarrhoea, are symptoms commonly associated to dysmenorrhea. In conclusion, piroxicam fast dissolving dosage form for sublingual administration, in the treatment of primary dysmenorrhea, showed its analgesic efficacy 15 minutes after the drug administration. It has also a good local and systemic tolerability.

Administration, Sublingual↗
PubMedDate not supplied

Efficacy of the association of 13-cis-retinoic acid (13cRA) and alpha-interferon 2a (alpha-IFN 2a) in moderate-severe cervical intraepithelial neoplasia (CIN II-III): a pilot study.

Recent in vitro studies have suggested a possible therapeutic synergism between alpha-IFN 2a and 13cRA in certain neoplasias, while encouraging in vivo findings strongly support the enhanced effectiveness of the two agents when used in combination. The specific aim of our study was to evaluate the efficacy and the toxicity of the association of 13cRA and alpha-IFN 2a in patients with CIN II and CIN III who refused surgical treatment. Twenty-one patients (aged between 25 and 58 years), of which 14 were CIN II and 7 CIN III, entered the study. 13cRA (orally at 0.5-1 mg/Kg/day) and alpha-IFN 2a (intramuscular at 3x10(6) I.U./day for the first 15 days, then 3 times/week for the following four weeks) were administered simultaneously for eight consecutive weeks. 13/21 (62%) histologically verified objective responses (6 complete and 7 partial) were achieved. We also obtained 8 stable diseases. Compliance was generally good and no delays in therapy due to toxicity were recorded (except for two patients presenting WHO degree III cutaneous and mucosal toxicity which regressed one week after suspending treatment). Human Papilloma Virus (HPV) was initially detected in 16/21 (76%) patients, while HPV negativization after treatment was observed in 3/16 (19%). Although preliminary and requiring long-term assessment, the encouraging results of this study confirm the need for further investigation on the role of systemic medical therapy in the treatment of CINs.

Adult↗